Last updated: September 8, 2026
Doripenem is a discontinued or commercially limited intravenous carbapenem whose financial trajectory was constrained by intense competition, hospital antimicrobial stewardship, safety concerns in ventilator-associated pneumonia, and the loss of U.S. exclusivity. The product, marketed as Doribax in the United States and Europe and as Finibax in Japan, never reached the commercial scale of meropenem or imipenem/cilastatin. Public company filings do not disclose a reliable standalone revenue series for doripenem.
The commercial position deteriorated materially after the FDA warned in 2014 that doripenem had produced higher mortality and lower clinical cure rates than imipenem/cilastatin in patients with ventilator-associated pneumonia. The U.S. brand was subsequently withdrawn, and doripenem became a low-volume generic hospital antibiotic rather than a significant branded franchise. [1][2]
What is doripenem and how was it commercialized?
Doripenem is a parenteral carbapenem antibacterial active against a broad range of gram-negative and gram-positive pathogens, including many beta-lactamase-producing organisms. It is administered intravenously and was approved for complicated intra-abdominal infections and complicated urinary tract infections.
| Item |
Detail |
| Active ingredient |
Doripenem monohydrate |
| Drug class |
Carbapenem beta-lactam antibiotic |
| Original developer |
Shionogi & Co., Ltd. |
| U.S. brand |
Doribax |
| Japanese brand |
Finibax |
| U.S. approval |
2007 |
| U.S. sponsor |
Johnson & Johnson/Janssen-related commercial organization |
| Primary dosage form |
Sterile powder for intravenous infusion |
| Initial U.S. indications |
Complicated intra-abdominal infection and complicated urinary tract infection |
| Commercial status |
Brand withdrawn from the U.S.; generic availability and international sales have been limited |
| Biosimilar exposure |
None; doripenem is a small molecule |
The FDA approved Doribax in November 2007 for adults with complicated intra-abdominal infection and complicated urinary tract infection. The approved dosing regimen was generally 500 mg intravenously every eight hours, with renal dose adjustment. [1]
Doripenem entered a crowded carbapenem market. Meropenem and imipenem/cilastatin already had substantial hospital adoption, broad clinical familiarity, and established procurement channels. Ertapenem occupied a once-daily niche for selected infections. Doripenem therefore needed to win share through spectrum, tolerability, dosing, or formulary economics rather than by creating a new treatment category.
How did doripenem revenue develop over time?
No public source provides a complete, audited, standalone global revenue history for doripenem. Johnson & Johnson reported pharmaceutical sales by broader product groupings and did not consistently identify Doribax as a separate material revenue line in annual reports. Shionogi similarly reported product-level information selectively by geography and product portfolio.
The financial trajectory can therefore be reconstructed from regulatory and commercial milestones rather than from a complete revenue series.
| Period |
Commercial phase |
Revenue implication |
| 2007-2009 |
U.S. launch and formulary placement |
Initial uptake, but limited by hospital-only intravenous use and competition |
| 2010-2012 |
Mature branded hospital product |
Sales constrained by established meropenem and imipenem use |
| 2013-2014 |
Safety and indication deterioration |
Demand weakened after failure of the ventilator-associated pneumonia program |
| 2014 onward |
Brand withdrawal and generic transition |
Branded revenue collapsed; market value shifted to low-margin injectable supply |
| Current market |
Fragmented generic and regional supply |
No evidence of a large global branded revenue stream |
The central financial problem was market access. Doripenem was used almost exclusively in institutional settings, where pharmacy and therapeutics committees evaluate clinical outcomes, antimicrobial resistance, acquisition cost, and stewardship restrictions. A hospital antibiotic with no oral formulation has a narrower commercial base than products that can support outpatient or step-down treatment.
The VAP outcome made the problem more severe. The FDA concluded that doripenem was associated with higher mortality and lower cure rates than imipenem/cilastatin in the relevant trial population. That finding weakened confidence in off-label expansion and reduced the probability that doripenem would become a preferred empiric option for severe hospital-acquired infections. [2]
When did doripenem lose exclusivity?
U.S. regulatory exclusivity ended before the product’s commercial withdrawal. Doripenem received new chemical entity exclusivity associated with its 2007 approval, which protected the product from abbreviated new drug approval based on the same active ingredient for five years, subject to applicable regulatory rules. The principal commercial patent protection also expired during the 2010s.
The key U.S. composition patent commonly associated with doripenem is U.S. Patent No. 5,965,677, assigned to Shionogi-related interests and directed to carbapenem compounds. Public patent records indicate that the patent issued in 1999 and had a term extending into the mid-2010s under the applicable U.S. patent-term framework. [3]
| Exclusivity category |
Approximate endpoint |
Commercial effect |
| U.S. five-year new chemical entity exclusivity |
2012 |
Removed the principal regulatory barrier to ANDA filing |
| Core composition patent protection |
Mid-2010s |
Opened the market to generic competition after patent expiry |
| Brand commercial position |
2014 |
Damaged by safety findings and withdrawal |
| Current branded exclusivity |
None identified |
Doripenem is no longer an active branded U.S. franchise |
Patent-term calculations can differ based on patent-term adjustment, terminal disclaimers, pediatric exclusivity, and the specific patent and product listing. The decisive commercial point is that no active U.S. exclusivity remains capable of supporting a premium branded doripenem business.
What patents protect doripenem?
Doripenem’s historical patent estate included composition-of-matter protection for carbapenem compounds, related salts and hydrates, pharmaceutical compositions, and manufacturing processes. The core commercial protection was the active pharmaceutical ingredient rather than a differentiated delivery system.
Composition and formulation protection
Doripenem is supplied as a sterile injectable powder that is reconstituted and diluted before intravenous infusion. Formulation protection historically could cover:
- Doripenem monohydrate;
- pharmaceutical compositions containing doripenem;
- stabilization against degradation;
- sterile powder preparation;
- reconstitution and infusion solutions; and
- manufacturing and purification processes.
These protections had less strategic value after expiration because generic injectable manufacturers could rely on the established active ingredient and develop non-infringing manufacturing and formulation processes.
Method-of-use patents
Doripenem’s principal approved uses were complicated intra-abdominal and complicated urinary tract infections. Method-of-use protection was commercially secondary to the composition patent and regulatory exclusivity.
The VAP development program did not strengthen the estate. The FDA’s safety communication instead limited the commercial value of using doripenem for ventilator-associated pneumonia. [2]
What is the Orange Book status of doripenem?
Doribax was historically listed in the FDA Orange Book as an approved prescription drug product. The relevant product was an injectable doripenem formulation, not an oral tablet or extended-release dosage form.
The Orange Book framework was commercially important during the period when generic applicants could challenge listed patents through Paragraph IV certifications. After the listed patent and regulatory exclusivity periods ended, the main barrier to ANDA approval became product development, sterile manufacturing, bioequivalence, and commercial supply rather than innovator patent protection. [4]
Doripenem did not create a durable Orange Book strategy based on multiple reformulations. Unlike some major drugs, it had no long-lived succession of oral, extended-release, device-based, or combination products capable of extending the franchise.
Which companies challenged doripenem patents?
The public record does not show a major, commercially consequential U.S. patent litigation campaign comparable with the litigation surrounding high-revenue small-molecule medicines. Doripenem’s generic threat was driven primarily by ordinary patent expiry and ANDA competition.
The absence of major high-value litigation is consistent with the product’s limited market size. Generic applicants have less incentive to incur substantial Paragraph IV litigation expense when the branded market is small, the product is hospital-administered, and the innovator has already withdrawn or reduced commercial support.
Generic entry was more likely to proceed through:
- patent-expiry-based ANDA approval;
- limited Paragraph IV exposure;
- regional tenders and institutional procurement;
- manufacturing competition; and
- price-based substitution.
The commercially relevant challengers were therefore generic injectable manufacturers rather than a single named branded rival. Public information identifies doripenem generic supply in international markets from multiple manufacturers, but the U.S. product-level sales impact cannot be quantified from public filings.
How did the FDA safety action affect doripenem demand?
The FDA issued a safety communication in 2014 after a clinical trial in ventilator-associated pneumonia was stopped early. The trial showed worse outcomes for doripenem than for imipenem/cilastatin. The FDA stated that doripenem should not be used for ventilator-associated pneumonia and required labeling changes. [2]
The effect on market dynamics was direct:
- VAP use became commercially unavailable as a growth pathway.
- Hospital formularies had less reason to add or retain doripenem.
- Physicians faced a higher perceived clinical and legal risk in severe pneumonia.
- Promotional differentiation narrowed to approved intra-abdominal and urinary indications.
- The remaining market became more dependent on price and supply reliability.
- The brand lost the opportunity to compete as a broad severe-infection carbapenem.
This event also changed the competitive comparison with meropenem and imipenem/cilastatin. Even where doripenem had attractive in vitro activity or dosing characteristics, the clinical safety signal impaired adoption.
How does doripenem compare with competing carbapenems?
| Product |
Administration |
Commercial position |
Competitive advantage |
| Doripenem |
Intravenous |
Limited generic and regional market |
Broad spectrum and historical hospital use |
| Meropenem |
Intravenous |
Major hospital carbapenem |
Extensive clinical familiarity and broad use |
| Imipenem/cilastatin |
Intravenous |
Established hospital product |
Long clinical history and broad availability |
| Ertapenem |
Intravenous or intramuscular |
Distinct once-daily niche |
Convenient dosing and lower anti-pseudomonal breadth |
| Tebipenem |
Oral, jurisdiction-dependent |
Developmental or regional opportunity |
Potential oral carbapenem convenience |
Doripenem’s most important commercial disadvantage was that it occupied the same institutional treatment environment as meropenem and imipenem/cilastatin without producing a clear enough outcome or convenience advantage.
Ertapenem was not a direct substitute for every doripenem use because it lacks activity against some important nonfermenting gram-negative pathogens, including Pseudomonas aeruginosa. Its once-daily dosing nevertheless gave it a strong position in selected outpatient parenteral and step-down settings.
What generic entry risks exist for doripenem?
Generic entry risk is high because:
- U.S. regulatory exclusivity has expired.
- Core patent protection has expired.
- Doripenem is a small molecule subject to the ANDA pathway.
- The product does not require biosimilar interchangeability analysis.
- No active branded reformulation appears to protect a substantial premium market.
- Hospitals routinely use tendering and therapeutic substitution.
The main barriers are operational rather than intellectual-property barriers. Injectable carbapenems require validated sterile manufacturing, reliable active pharmaceutical ingredient supply, stability data, container-closure controls, and regulatory compliance. These requirements can limit the number of active suppliers even after patent expiry.
A generic manufacturer also faces demand risk. A product may be approved but generate low sales if hospitals prefer meropenem or if antimicrobial stewardship programs restrict carbapenem use. Doripenem’s commercial opportunity is therefore more likely to depend on supply shortages, regional tenders, and price discounts than on broad market conversion.
What licensing deals shaped doripenem’s commercial trajectory?
Shionogi developed doripenem and commercialized it under regional arrangements, including the Doribax relationship with Johnson & Johnson in the United States and other markets. Shionogi retained a major role in Japan, where the product was marketed as Finibax.
The licensing structure gave doripenem access to multinational commercialization infrastructure but did not overcome its underlying market limitations. The product required hospital sales coverage, infectious-disease education, formulary negotiations, and postmarketing risk management. Those costs were difficult to support after the product lost differentiation and faced safety concerns.
No current high-value licensing transaction has established doripenem as a growth asset. Its commercial rights are now more relevant to generic supply and regional distribution than to branded business development.
What is the current financial exposure to doripenem?
Current financial exposure is low relative to major antibiotic franchises. The following factors suppress value:
- no active U.S. brand premium;
- no meaningful patent moat;
- no biologic or specialty-drug pricing;
- limited use outside hospitals;
- strong competition from established carbapenems;
- antimicrobial stewardship restrictions;
- safety concerns in VAP; and
- lack of an oral or long-acting formulation.
The remaining economic opportunity is concentrated in generic injectable supply, especially where a manufacturer can secure hospital contracts, exploit temporary shortages, or provide dependable supply at competitive pricing.
Doripenem is therefore better analyzed as a mature, low-value anti-infective product than as an active pharmaceutical growth asset. Its value may be operational for a generic manufacturer with sterile capacity, but it is unlikely to support a meaningful branded acquisition premium.
What generic launch scenarios are most likely?
Low-price institutional supply
A manufacturer can compete through hospital tenders and distributor contracts. Margins would likely be limited, but a reliable product can retain share where hospitals need multiple carbapenem suppliers.
Shortage-driven substitution
Temporary shortages of meropenem or imipenem/cilastatin could create episodic demand for doripenem. This opportunity would be volatile and dependent on regulatory-listed supply disruptions.
Regional market expansion
Doripenem may retain value in Japan and selected international markets where Finibax or local generic products have established regulatory status. Geographic performance will depend on local reimbursement, procurement, resistance patterns, and registration status.
Manufacturing-asset strategy
The strongest commercial rationale is vertical integration with sterile injectable manufacturing and an existing hospital portfolio. Doripenem alone is unlikely to justify major investment in a new sterile facility.
How strong is the doripenem patent estate today?
The current patent estate is weak as a commercial defense. Historical composition and formulation patents supported the launch period, but the relevant U.S. protection has expired. Any remaining value is more likely to arise from manufacturing know-how, regulatory approvals, supplier qualification, and hospital contracts than from enforceable exclusivity.
Geographic coverage also matters. Patent expiry and regulatory status differ by country, and some jurisdictions may have maintained local products or licensing arrangements after U.S. commercialization ended. That geographic variation does not recreate a meaningful global branded moat.
Key Takeaways
- Doripenem was approved in the U.S. in 2007 as Doribax for complicated intra-abdominal and urinary tract infections.
- The product competed directly with meropenem and imipenem/cilastatin in a mature hospital market.
- The FDA’s 2014 VAP safety warning materially reduced clinical and commercial confidence.
- U.S. regulatory exclusivity and core patent protection expired during the 2010s.
- No current U.S. branded exclusivity supports a premium doripenem franchise.
- Generic-entry risk is high, while litigation risk is comparatively low because the branded market is small.
- Current value is concentrated in regional generic supply, hospital tenders, shortage substitution, and sterile-manufacturing capabilities.
- Public filings do not provide a reliable standalone doripenem revenue series.
- Doripenem has no biosimilar risk because it is a small-molecule antibiotic.
- The product’s financial trajectory is one of launch, limited hospital adoption, safety-driven decline, brand withdrawal, and low-margin generic continuation.
FAQs About Doripenem Market and Patent Exposure
Is doripenem still sold in the United States?
The branded U.S. product Doribax is no longer a meaningful commercial franchise. Generic doripenem availability may vary by manufacturer, channel, and current supply status.
Is doripenem protected by an active U.S. patent?
No active composition-of-matter or formulation patent is known to provide meaningful current U.S. exclusivity for doripenem. The principal historical protection expired during the 2010s.
Can a generic manufacturer file an ANDA for doripenem?
Yes. Doripenem is a small molecule eligible for the ANDA pathway, subject to FDA requirements for pharmaceutical equivalence, bioequivalence, sterile manufacturing, labeling, and quality controls.
Why did doripenem fail in ventilator-associated pneumonia?
The FDA reported higher mortality and lower clinical cure rates for doripenem than for imipenem/cilastatin in a VAP trial. The agency required labeling changes and advised against doripenem use for VAP. [2]
Does doripenem have a meaningful biosimilar market?
No. Biosimilar regulation applies to biologic products. Doripenem is a chemically synthesized small-molecule antibiotic, so competition occurs through generic drug applications rather than biosimilar applications.
References
-
U.S. Food and Drug Administration. (2007). Doribax (doripenem for injection) prescribing information. FDA.
-
U.S. Food and Drug Administration. (2014). FDA Drug Safety Communication: FDA warns of increased risk of death and lower cure rates with Doribax for injection in patients with ventilator-associated bacterial pneumonia. FDA.
-
U.S. Patent and Trademark Office. (1999). U.S. Patent No. 5,965,677, carbapenem compounds. USPTO.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
Johnson & Johnson. (2008-2014). Annual reports. Johnson & Johnson.
-
Shionogi & Co., Ltd. (2007-2015). Annual reports and investor materials. Shionogi & Co., Ltd.
